Aquipta is indicated for: - acute treatment of migraine with or without aura in adults - prophylaxis of migraine in adults who have at least 4 migraine days per month.
QULIPTA — ABBVIE, approved 2025-09-30 (NDA215206).
5,443 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.